The European Commission has approved a new regimen using pembrolizumab, a widely used immunotherapy drug, for the treatment of resectable locally advanced head and neck squamous cell carcinoma (LA-HNSCC). This decision is considered a major milestone in European oncology, offering renewed hope for patients with one of the most aggressive and recurrent cancers.

Head and neck cancers are often detected at a late stage, making them difficult to treat and more likely to return. For decades, surgery and radiation have formed the backbone of treatment. With this approval, immunotherapy is now officially part of the perioperative pathway (before and after surgery), marking a fundamental shift in how clinicians approach curative treatment.

What Is Pembrolizumab?

Pembrolizumab is a PD-1 inhibitor, a type of immunotherapy that has been authorised by global regulators, including the European Medicines Agency (EMA), U.S. FDA, UK MHRA, CDSCO, and several Asian agencies, for multiple cancers, such as melanoma, lung cancer, cervical cancer, and bladder cancer.

It works by enabling the body’s immune system to recognise and destroy cancer cells—effectively unleashing immune activity that tumours often suppress.

What Does the New EU Approval Mean?

The latest approval allows pembrolizumab to be used in patients with resectable, locally advanced HNSCC:

• Before surgery (neoadjuvant treatment)
• After surgery combined with radiotherapy (adjuvant treatment)

The decision is based on strong clinical evidence showing that pembrolizumab significantly improves outcomes, particularly in patients whose tumours express PD-L1, a biomarker that predicts a better response to this form of immunotherapy.

Key Clinical Evidence (Phase 3 Trial)

The EMA’s approval draws on results from a large, international Phase 3 trial evaluating pembrolizumab in the perioperative setting.

Key findings include:

• Patients receiving pembrolizumab lived longer without disease progression compared with patients who received the standard of care (surgery plus radiation).
• Those with PD-L1–positive tumours experienced the greatest benefit.
• The regimen reduced the risk of recurrence, disease progression, or death by about 30%.
• These results represent one of the most significant advances in head and neck cancer therapy in recent years.

Other regulators, including the FDA and Japan’s PMDA, are evaluating similar datasets, suggesting a global shift toward adopting this approach.

Why Is This Approval Important?

Head and neck cancers remain a major public health concern:

• Approximately 160,000 new cases occur in Europe each year.
• Nearly 70,000 deaths are reported annually.
• The disease is strongly associated with tobacco use, alcohol consumption, and HPV infection.
• Treatment is challenging due to the involvement of sensitive areas such as the throat, tongue, and voice box.

Standard treatments, while crucial, often carry significant side effects and a high risk of recurrence. Adding immunotherapy aims to:

• Strengthen the immune defence system before surgery.
• Reduce the risk of the cancer returning after treatment.
• Improve both survival and quality of life.

Clinicians view this as a major step toward precision oncology, where therapies are tailored based on biological markers rather than applied universally.

Safety and Side Effects

According to data from the EMA, FDA, and other regulatory authorities, pembrolizumab is generally safe when used under medical supervision. Common side effects include:

• Fatigue
• Skin rash
• Diarrhoea
• Itching
• Loss of appetite

Because pembrolizumab amplifies immune activity, it can occasionally cause inflammation in organs such as the lungs, liver, or thyroid. These reactions are usually manageable with early detection, underscoring the importance of ongoing monitoring throughout treatment.

What Happens Next?

With EMA approval granted, each EU member state will begin assessing reimbursement and pricing. Oncology specialists and patient advocacy groups hope the regimen will soon become part of standard care across Europe.

Wider adoption could:

• Improve long-term survival
• Delay or prevent recurrence
• Reduce emotional strain on families
• Lower long-term healthcare costs

This approval also highlights the EMA’s continued commitment to encouraging evidence-based innovation and ensuring timely access to effective therapies.

Conclusion

The approval of pembrolizumab for resectable LA-HNSCC is more than an additional treatment option—it represents a transformative shift in cancer management. By integrating immunotherapy before and after surgery, Europe is moving towards more personalised, effective, and hope-driven cancer care.

If embraced globally, this approach has the potential to reshape treatment standards for head and neck cancers worldwide.